Abstract
The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC₅₀/MIC₉₀ to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs ≤ 4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC₅₀ and MIC₉₀ of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amikacin / pharmacology
-
Anti-Bacterial Agents / pharmacology*
-
Drug Resistance, Multiple, Bacterial*
-
Enterobacter / drug effects*
-
Enterobacter / isolation & purification
-
Enterobacter / metabolism
-
Enterobacteriaceae Infections / microbiology
-
Escherichia coli / drug effects*
-
Escherichia coli / isolation & purification
-
Escherichia coli / metabolism
-
Escherichia coli Infections / microbiology
-
Gentamicins / pharmacology
-
Greece
-
Humans
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / isolation & purification
-
Klebsiella pneumoniae / metabolism
-
Microbial Sensitivity Tests
-
Sisomicin / analogs & derivatives*
-
Sisomicin / pharmacology
-
Tertiary Care Centers
-
Tobramycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Gentamicins
-
Amikacin
-
plazomicin
-
Tobramycin
-
Sisomicin